ethoheptazine

Ethoheptazine is a phenazepine-based opioid analgesic developed in the 1950s. It is structurally related to proheptazine and pethidine and was primarily used for the relief of mild to moderate pain. Ethoheptazine acts as an opioid analgesic, producing effects such as analgesia, sedation, dizziness, and nausea similar to other opioids. Its mechanism of action is believed to involve binding to mu-opioid receptor in the central nervous system. Ethoheptazine was marketed under the brand name Zactane and also available in combination with acetylsalicylic acid and meprobamate as Equagesic for conditions involving both pain and anxiety. The drug has been withdrawn from markets worldwide due to concerns over efficacy compared with toxicity and safer alternatives; it is no longer FDA approved or available in the United States[1][2][3][4][5][6][7].

Brand names

ZactaneEquagesic

Other names

ZactaneEquagesic